Eli Lilly SURMOUNT-5 sub-study finds tirzepatide slows all 15 biological aging clocks, some moving backward

An epigenetic sub-study from Eli Lilly's SURMOUNT-5 trial, presented at an aging research conference at Harvard, found that all 15 biological aging clocks advanced more slowly than chronological time in patients taking tirzepatide, with some even moving backward.

Detected & updated continuously · Source: Nebula